Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.The duration of the response is, however, limited Hubs in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET o

read more



Robust Communication Design in RIS-Assisted THz Channels

Terahertz (THz) communication offers the necessary bandwidth to meet the high data rate demands of next-generation wireless systems.However, it faces significant challenges, including severe path loss, dynamic blockages, and beam misalignment, which jeopardize communication reliability.Given that many 6G use cases require both high data rates and s

read more